— Know what they know.
Not Investment Advice

ALDX NASDAQ

Aldeyra Therapeutics, Inc.
1W: -4.2% 1M: -6.5% 3M: -67.9% YTD: -66.0% 1Y: -32.6% 3Y: -84.1% 5Y: -86.9%
$1.55
-0.04 (-2.52%)
 
Weekly Expected Move ±7.0%
$1 $2 $2 $2 $2
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 35 · $93.5M mcap · 58M float · 5.32% daily turnover · Short 42% of daily vol

Balance Sheet Trends

Total Assets
$72M -31.1% ▼
5Y CAGR: -2.9%
Total Liabilities
$28M -17.2% ▼
5Y CAGR: +3.1%
Shareholders Equity
$44M -37.7% ▼
5Y CAGR: -5.8%
Cash & Investments
$70M -30.8% ▼
5Y CAGR: -2.1%
Total Debt
$16M +1.5% ▲
5Y CAGR: +0.3%
Net Debt
-$55M -39.0% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$230M$144M$143M$55M$70M
Short-Term Investments$0$30M$0$47M$0
Cash & ST Investments$230M$174M$143M$101M$70M
Net Receivables$29K$3M$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$2M$3M$5M$3M$1M
Total Current Assets$233M$181M$148M$104M$72M
Property, Plant & Equip.$384K$269K$517K$267K$276K
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$0$0$0$267K$0
Total Non-Current Assets$384K$269K$517K$534K$276K
Total Assets$233M$181M$148M$105M$72M
— Liabilities —
Accounts Payable$1M$134K$1M$180K$158K
Short-Term Debt$0$912K$15M$31K$15M
Deferred Revenue$0$0$0$6M$6M
Other Current Liabilities$2M$4M$3M$4M$4M
Total Current Liabilities$12M$15M$22M$19M$28M
Long-Term Debt$16M$15M$0$15M$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$16M$15M$6M$15M$0
Total Liabilities$27M$30M$29M$34M$28M
— Equity —
Common Stock$58K$59K$59K$60K$60K
Retained Earnings-$295M-$357M-$394M-$450M-$484M
Accumulated OCI$0-$104K$0$37K$0
Total Stockholders Equity$206M$151M$120M$71M$44M
Total Liabilities & Equity$233M$181M$148M$105M$72M
— Key Metrics —
Total Debt$16M$16M$16M$15M$16M
Net Debt-$214M-$128M-$127M-$39M-$55M
Total Investments$0$30M$0$47M$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms